The patient has received any investigational therapy within 4 weeks of enrollment
Use of any investigational drugs, biologics, or devices within 30 days prior or during the study treatment.
Use of other investigational drugs at the time of screening or within the last 30 days.
Any investigational agents or drugs from a previous clinical study within 28 days
Use of other investigational drugs within 28 days prior to study drug administration
Investigational Drugs: Subjects who have received another investigational drug within the last 14 days are excluded from participation.
Other investigational drugs or investigational therapy if the patient is currently taking those drugs/therapy, or if they have received the drugs/therapy within 1 month.
Treatment with any investigational compound within 30 days prior to the first dose of study drugs
Subjects taking other investigational drugs or drugs of abuse within 30 days of entry into this study.
Patients receiving other investigational immunotherapy or anti-myeloma drugs within 14 days before enrollment.
Receipt of an investigational agent within 28 days (or 56 days for an antibody-based therapy) before the first planned dose of study drugs
Within 14 days of the first dose of the study drugs: Platelets >= 75,000/L.
Patient has used any investigational drugs, biologics (vaccines, antibodies), or devices within 30 days prior to study treatment or has plans to use any of these during the course of the study
Patient is receiving other investigational drugs
Have received other investigational drugs within 30 days of enrollment.
Participated in a previous clinical trial or used any investigational drugs, biologics, or devices within 90 days prior to study treatment or plans to use any of these during the course of the study.
Received any investigational drugs within the 14 days prior to CIML NK cell infusion date
Received investigational drugs within the 14 days before 1st dose of study drug
Investigational drugs: subjects must not have received an investigational drug within 4 weeks
Patient has received other investigational drugs with 14 days before enrollment
Received any investigational drugs within the 14 days prior to the first day of transplant conditioning
Patients who have received other investigational drugs within 14 days prior to screening
Receipt of an investigational agent within 28 days (or 60 days for an antibody-based therapy) before the first planned dose of study drugs
Exposure to other investigational drugs within 4 weeks before enrollment
Patients who are receiving other investigational drugs 14 or fewer days before enrollment
Have received other investigational drugs within 14 days prior to enrollment
Treatment with any investigational compound within 30 days prior to the first dose of study drugs
Patient has received other investigational drugs with 14 days before enrollment
Use of any investigational drugs within 30 days prior to dosing
Patients who have received other investigational drugs within 28 days of Viralym-A infusion.
Patient has received other investigational drugs within 14 days before enrollment
Investigational Drugs: Subjects who have received another investigational drug within the last 14 days are excluded from participation.
Treatment with other investigational drugs within 6 months of study entry
Patient has received other investigational drugs within 4 weeks before enrollment
Received any investigational drugs within the 14 days prior to the first dose of fludarabine
Exposure to other investigational drugs within 2 weeks before enrollment
Patient has received other investigational drugs within 3 weeks before study registration
Used any investigational drugs, biologics, or devices within 30 days prior to study treatment or plans to use any of these during the course of the study.
Subjects who have received any investigational drugs or devices within 4 weeks before the first day of study treatment (C1D1).
Received any investigational drugs within the 14 days before 1st dose of fludarabine
Use of other investigational drugs
Have received either of the study drugs
Participants who are receiving, or have received, any other investigational drugs or devices within the 2 weeks prior to the first dose of study medications
Patients who have received hepatotoxic drugs less than 7 days prior to enrollment
Received investigational drugs within the 14 days of study registration
Use of other investigational drugs within 28 days preceding the first dose of trametinib and during the study
Concomitant use of any other investigational drugs
Concurrent treatment with other investigational drugs.
Patient has received other investigational drugs with 14 days before treatment of treatment with bortezomib + rituximab
Used any investigational drugs, biologics, or devices within 30 days prior to study treatment or plans to use any of these during the course of the study.
Patient has received other investigational drugs with 14 days before enrollment
Currently receiving or has received any investigational drugs within the 14 days prior to the first dose of study drug (day -7)
Subjects who have received investigational drugs =< 4 weeks prior to registration
Patients on other investigational drugs while on study will be excluded
Receipt of an investigational agent within 28 days (or 56 days for an antibody-based therapy) before the first planned dose of study drugs
Patient has used any investigational drugs, biologics, or devices within 30 days prior to study treatment or plans to use any of these during the course of the study.
Subject has received other investigational drugs within 14 days prior to first dose of study drug.
Other investigational drugs within 4 weeks prior to enrollment, unless cleared by the Principal Investigator
Use of other investigational drugs within 28 days preceding the first dose of vemurafenib during this study
Investigational drugs: subjects must not have received an investigational drug within 4 weeks
Any investigational agents or study drugs from a previous clinical study within 30 days of the first dose of study treatment;
Prior use of investigational drugs =< 14 days prior to registration
Patient has received other investigational drugs with 14 days before enrollment
Patient has received other investigational drugs with 14 days before enrollment
Concomitant use of any other investigational drugs
Receipt of an investigational agent within 30 days (or 60 days for an antibody-based therapy) before the first planned dose of study drugs
Taking other investigational drugs
Concomitant use of any other investigational drugs
Concurrent use of other investigational agents and patients who have received investigational drugs =< 4 weeks prior to enrollment
Patient has received other investigational drugs within 3 weeks before study registration
Received investigational drugs within the 14 days before enrollment
Received any investigational drugs within the 14 days before 1st dose of fludarabine
Patient has received other investigational drugs within 14 days prior to enrollment
Patient has received other investigational drugs with 14 days before enrollment
Patient has received other investigational drugs with 14 days before enrollment
Patient has received other investigational drugs with 14 days before enrollment.
Patient has not received other investigational drugs with 14 days before enrollment
Receipt of investigational drugs within 14 days before D1 of alisertib
Use of any investigational drugs, biologics, or devices within 28 days prior to study enrollment
Subjects receiving concomitant treatment with radiotherapy or other investigational drugs
Concomitant use of any other investigational drugs
Patient has received other investigational drugs or chemotherapy within 21 days or approved anti-myeloma therapy within 14 days.
Patient has received other investigational drugs with 14 days before enrollment
Patient has received other investigational drugs within 1 week before enrollment.
Patients who have received other investigational drugs within 28 days of Viralym-C infusion
Use of other investigational drugs within 28 days preceding the first dose of vemurafenib on this study.
Use of other investigational drugs
Have taken any of the following drugs within 7 days prior to Study Day 1:
Patient has received other investigational drugs with 14 days before enrollment
Patient has received other investigational drugs with 14 days before enrollment
Use of anti-cancer treatment (including investigational drugs) within 28 days
Patients receiving concurrent investigational drugs
Patient has received other investigational drugs within 14 days of treatment initiation
Investigative drugs within 21 days
Concurrent investigational drugs
Patient has received other investigational drugs within 14 days before enrollment or who have not recovered from side effects of those therapies
Any treatment with investigational drugs within 30 days before the start of the study
Have received other investigational drugs within 28 days prior to enrollment
Other investigational drugs within 4 weeks prior to enrollment, unless cleared by the principal investigator
Concurrent participation in another study involving investigational drugs or investigational medical devices
Patient has used any investigational drugs, biologics, or devices within 14 days prior to study treatment or plans to use any of these during the course of the study
Currently receiving or has received any investigational drugs within the 14 days prior to the first dose of the conditioning regimen
Not receiving any other investigational agents (i.e., unlabeled drugs or drugs under an investigational new drug [IND] for initial efficacy investigations)
Not receiving any other investigational agents (i.e., unlabeled drugs or drugs under an investigational new drug (IND) for initial efficacy investigations
Has received investigational drugs suspected to cause peripheral neuropathy; no concurrent investigational drugs may be used
Investigational drugs: must not be receiving other investigational (from other studies) drugs at time of enrollment and must not be planning to take other investigational drugs during DLT period
Other investigational drugs
